he main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.
The purpose of this study is to evaluate sustained virologic response 12 weeks after the end of treatment (SVR12) following 12 weeks of simeprevir plus sofosbuvir with and without ribavirin (RBV) and 24 weeks of simeprevir plus sofosbuvir without RBV in post orthotopic liver transplant participants with recurrent hepatitis (inflammation of the liver) C virus (HCV) Genotype 1 infection.
This is a study to evaluate chronic Hepatitis C Virus infection.
The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
Long term follow up for CTOTC-04 patients and 2 year observational study looking at allo-antibodies in newly transplanted patients both sensitized and non sensitized.
The purpose of this pilot trial, Transitioning to Adult Care (TRANSIT), is to develop and test an intervention (i.e., a standardized, tailored transition program focused on enhancing adherence) to improve outcomes for emerging adults who underwent heart transplantation as children and transfer to adult care.
To determine the ability of established and novel cardiac biomarkers to predict short- and long-term outcomes.
To determine outcomes following ABO incompatible pediatric heart transplants.
Prospective cohort study of pediatric cases of DCM, HCM, and RCM aiming to identify new disease-causing and disease-associated mutations as well as geno-phenotypes cardiomyopathy.